Avatrombopag
Avatrombopag[edit]
Avatrombopag is a medication used primarily to treat thrombocytopenia, a condition characterized by abnormally low levels of platelets in the blood. It is particularly used in patients with chronic liver disease who are scheduled to undergo a medical or dental procedure, as well as in patients with chronic immune thrombocytopenic purpura (ITP).
Mechanism of Action[edit]
Avatrombopag is a thrombopoietin receptor agonist. It works by stimulating the production of platelets in the bone marrow. The drug binds to the thrombopoietin receptor on the surface of megakaryocytes and their precursors, promoting their proliferation and differentiation into platelets. This mechanism helps increase platelet counts in patients with thrombocytopenia.
Clinical Use[edit]
Avatrombopag is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. It is also used in adult patients with chronic immune thrombocytopenic purpura who have had an insufficient response to previous treatment.
Administration[edit]
Avatrombopag is administered orally. The dosage and duration of treatment depend on the specific condition being treated and the patient's platelet count. It is important for patients to follow their healthcare provider's instructions regarding dosage and administration.
Side Effects[edit]
Common side effects of avatrombopag include headache, fatigue, and nausea. Serious side effects may include thromboembolic events, such as deep vein thrombosis or pulmonary embolism. Patients should be monitored for signs of increased platelet counts and potential thrombotic complications.
Pharmacokinetics[edit]
Avatrombopag is absorbed in the gastrointestinal tract and reaches peak plasma concentrations approximately 3 to 6 hours after administration. It is metabolized primarily in the liver and excreted in the feces. The half-life of avatrombopag is approximately 19 hours, allowing for once-daily dosing.
Development and Approval[edit]
Avatrombopag was developed by Eisai Co., Ltd., a Japanese pharmaceutical company. It was approved by the U.S. Food and Drug Administration (FDA) in 2018 for the treatment of thrombocytopenia in patients with chronic liver disease scheduled to undergo a procedure. It was later approved for use in patients with chronic immune thrombocytopenic purpura.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
